Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA 2017 First Generics Approvals Retain India Imprint

Executive Summary

Indian companies continued to have marked presence in list of first generics approved by US FDA in 2017; clearances include some limited competition drugs and complex products that are vital for Indian firms as they transition their portfolios away from 'plain vanilla' generics.

You may also be interested in...



Sun Outstrips Viatris’ Pentasa Action Date With First ANDA Approval

Sun Pharma has scooped a first ANDA approval for a rival to Takeda’s mesalamine-containing brand Pentasa, with Viatris making clear recently that it was eyeing a first-time generic launch for the gastrointestinal drug.

Copaxone 40mg Generic: FDA Exceeds Mylan's Expectations

FDA approves the product well before Mylan's prediction of 2018.

Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication

By conducting a product development or pre-submission meeting, sponsors can receive a mid-review cycle meeting for a complex product ANDA.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB002330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel